



ANDA 215837

ANDA APPROVAL

Sun Pharmaceutical Industries, Inc.
U.S. Agent for Sun Pharmaceutical Industries Limited
2 Independence Way
Princeton, NJ 08540
Attention: Juan Grijalva
Regulatory Manager

Dear Juan Grijalva:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on March 31, 2022, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Pazopanib Tablets, 200 mg.

Reference is also made to the tentative approval letter issued by this office on May 24, 2023, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. Accordingly the ANDA is **approved**, effective on the date of this letter. We have determined your Pazopanib Tablets, 200 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, 200 mg, of Novartis Pharmaceuticals Corporation.

Reference is also made to FDA's Competitive Generic Therapy (CGT) Designation – Grant letter dated March 31, 2021.

We note that Sun Pharmaceutical Industries Limited (Sun) was granted a Competitive Generic Therapy (CGT) designation for Pazopanib Tablets, 200 mg. However, as noted in the March 31, 2021 CGT Designation – Grant Letter, your drug product is not eligible for CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act because there was an unexpired patent or exclusivity listed in FDA's *Approved Drug Products With Therapeutic Equivalence Evaluations* (Orange Book) for the RLD at the time of submission of your ANDA.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA referencing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standard for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website as <https://www.uspnf.com/>.

REQUIREMENTS AND RECOMMENDATIONS POST APPROVAL

Under applicable statutes, regulations, and guidances, your ANDA may be subject to certain requirements and recommendations post approval, including requirements regarding changes to approved ANDAs, postmarketing reporting, promotional materials, and annual facility fees, among others. For information on post-approval requirements and recommendations for ANDAs and a list of resources for ANDA holders, we refer you to <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/requirements-and-resources-approved-andas>.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research



Catherine
Poole

Digitally signed by Catherine Poole

Date: 10/19/2023 08:08:03AM

GUID: 5407887a000a1c0c26055eafb8e3258a